The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CPDC     azanide; dichloroplatinum

Synonyms: S1166_Selleck, AC-2109, CHEBI:122989, Neuro_000055, NSC-131558, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of cisplatin


Psychiatry related information on cisplatin


High impact information on cisplatin


Chemical compound and disease context of cisplatin


Biological context of cisplatin


Anatomical context of cisplatin


Associations of cisplatin with other chemical compounds


Gene context of cisplatin


Analytical, diagnostic and therapeutic context of cisplatin

  • A therapeutic trial remains the only method to determine if patients have responsive tumors, and several patients who do not conform to a defined subset do respond to cisplatin-based chemotherapy [35].
  • For the Gynecologic Oncology Group, we conducted a trial to determine whether weekly infusions of cisplatin during radiotherapy improve progression-free and overall survival among patients with bulky stage IB cervical cancer [36].
  • We enrolled 53 consecutive patients with muscle-invading bladder cancer (stages T2 through T4, NXM0) in a trial of transurethral surgery, combination chemotherapy, and irradiation (4000 cGy) with concurrent cisplatin administration [37].
  • CONCLUSIONS: The neurokinin-1-receptor antagonist L-754,030 prevents delayed emesis after treatment with cisplatin [18].
  • We conclude that two courses of cisplatin-based adjuvant chemotherapy will almost always prevent relapse in pathological Stage II testicular cancer treated with orchiectomy and retroperitoneal-lymph-node dissection [38].


  1. Cisplatin toxicity for erythroid precursors. Rothmann, S.A., Weick, J.K. N. Engl. J. Med. (1981) [Pubmed]
  2. Treatment of ovarian cancer with intraperitoneal cisplatin. Beltran, M., Fuentes, R., Izquierdo, A. N. Engl. J. Med. (1997) [Pubmed]
  3. Treatment of non-small-cell lung cancer with cisplatin and radiotherapy. Katz, H.R. N. Engl. J. Med. (1992) [Pubmed]
  4. Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antagonist. Roila, F., Ballatori, E., Del Favero, A. N. Engl. J. Med. (1999) [Pubmed]
  5. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. Turrisi, A.T., Kim, K., Blum, R., Sause, W.T., Livingston, R.B., Komaki, R., Wagner, H., Aisner, S., Johnson, D.H. N. Engl. J. Med. (1999) [Pubmed]
  6. Severe tissue necrosis after cisplatin extravasation at low concentration: possible "immediate recall phenomenon". Bairey, O., Bishara, J., Stahl, B., Shaklai, M. J. Natl. Cancer Inst. (1997) [Pubmed]
  7. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Gao, W.Q., Dybdal, N., Shinsky, N., Murnane, A., Schmelzer, C., Siegel, M., Keller, G., Hefti, F., Phillips, H.S., Winslow, J.W. Ann. Neurol. (1995) [Pubmed]
  8. Repair of cisplatin--DNA adducts by the mammalian excision nuclease. Zamble, D.B., Mu, D., Reardon, J.T., Sancar, A., Lippard, S.J. Biochemistry (1996) [Pubmed]
  9. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity. Serkies, K., Jassem, J. Int. J. Radiat. Oncol. Biol. Phys. (2004) [Pubmed]
  10. Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy. Gregory, R.K., Hill, M.E., Moore, J., A'Hern, R.P., Johnston, S.R., Blake, P., Shephard, J., Barton, D., Gore, M.E. Eur. J. Cancer (2000) [Pubmed]
  11. The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair. Bridge, W.L., Vandenberg, C.J., Franklin, R.J., Hiom, K. Nat. Genet. (2005) [Pubmed]
  12. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O'Reilly, T., Natt, F., Hall, J., Lane, H.A., Thomas, G. Cell (2005) [Pubmed]
  13. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Katayama, H., Sasai, K., Kawai, H., Yuan, Z.M., Bondaruk, J., Suzuki, F., Fujii, S., Arlinghaus, R.B., Czerniak, B.A., Sen, S. Nat. Genet. (2004) [Pubmed]
  14. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. Keller, S.M., Adak, S., Wagner, H., Herskovic, A., Komaki, R., Brooks, B.J., Perry, M.C., Livingston, R.B., Johnson, D.H. N. Engl. J. Med. (2000) [Pubmed]
  15. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. Arriagada, R., Le Chevalier, T., Pignon, J.P., Rivière, A., Monnet, I., Chomy, P., Tuchais, C., Tarayre, M., Ruffié, P. N. Engl. J. Med. (1993) [Pubmed]
  16. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. Williams, S.D., Birch, R., Einhorn, L.H., Irwin, L., Greco, F.A., Loehrer, P.J. N. Engl. J. Med. (1987) [Pubmed]
  17. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. Cubeddu, L.X., Hoffmann, I.S., Fuenmayor, N.T., Finn, A.L. N. Engl. J. Med. (1990) [Pubmed]
  18. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. Navari, R.M., Reinhardt, R.R., Gralla, R.J., Kris, M.G., Hesketh, P.J., Khojasteh, A., Kindler, H., Grote, T.H., Pendergrass, K., Grunberg, S.M., Carides, A.D., Gertz, B.J. N. Engl. J. Med. (1999) [Pubmed]
  19. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. Nichols, C.R., Roth, B.J., Heerema, N., Griep, J., Tricot, G. N. Engl. J. Med. (1990) [Pubmed]
  20. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Takahara, P.M., Rosenzweig, A.C., Frederick, C.A., Lippard, S.J. Nature (1995) [Pubmed]
  21. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Ohndorf, U.M., Rould, M.A., He, Q., Pabo, C.O., Lippard, S.J. Nature (1999) [Pubmed]
  22. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S.V., Mathew, C.G., Joenje, H., Mok, S.C., D'Andrea, A.D. Nat. Med. (2003) [Pubmed]
  23. Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Fuertes, M.A., Alonso, C., Pérez, J.M. Chem. Rev. (2003) [Pubmed]
  24. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Gong, J.G., Costanzo, A., Yang, H.Q., Melino, G., Kaelin, W.G., Levrero, M., Wang, J.Y. Nature (1999) [Pubmed]
  25. Treatment of hepatic metastases in ocular melanoma. Embolization of the hepatic artery with polyvinyl sponge and cisplatin. Carrasco, C.H., Wallace, S., Charnsangavej, C., Papadopoulos, N.E., Patt, Y.Z., Mavligit, G.M. JAMA (1986) [Pubmed]
  26. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. Kaufmann, S.H., Peereboom, D., Buckwalter, C.A., Svingen, P.A., Grochow, L.B., Donehower, R.C., Rowinsky, E.K. J. Natl. Cancer Inst. (1996) [Pubmed]
  27. Treatment-associated leukemia following testicular cancer. Travis, L.B., Andersson, M., Gospodarowicz, M., van Leeuwen, F.E., Bergfeldt, K., Lynch, C.F., Curtis, R.E., Kohler, B.A., Wiklund, T., Storm, H., Holowaty, E., Hall, P., Pukkala, E., Sleijfer, D.T., Clarke, E.A., Boice, J.D., Stovall, M., Gilbert, E. J. Natl. Cancer Inst. (2000) [Pubmed]
  28. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. Travis, L.B., Holowaty, E.J., Bergfeldt, K., Lynch, C.F., Kohler, B.A., Wiklund, T., Curtis, R.E., Hall, P., Andersson, M., Pukkala, E., Sturgeon, J., Stovall, M. N. Engl. J. Med. (1999) [Pubmed]
  29. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. Alberts, D.S., Liu, P.Y., Hannigan, E.V., O'Toole, R., Williams, S.D., Young, J.A., Franklin, E.W., Clarke-Pearson, D.L., Malviya, V.K., DuBeshter, B. N. Engl. J. Med. (1996) [Pubmed]
  30. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. Levitt, M., Warr, D., Yelle, L., Rayner, H.L., Lofters, W.S., Perrault, D.J., Wilson, K.S., Latreille, J., Potvin, M., Warner, E. N. Engl. J. Med. (1993) [Pubmed]
  31. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. Markman, M., Sheidler, V., Ettinger, D.S., Quaskey, S.A., Mellits, E.D. N. Engl. J. Med. (1984) [Pubmed]
  32. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Brown, S.J., Kellett, P.J., Lippard, S.J. Science (1993) [Pubmed]
  33. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Slupianek, A., Schmutte, C., Tombline, G., Nieborowska-Skorska, M., Hoser, G., Nowicki, M.O., Pierce, A.J., Fishel, R., Skorski, T. Mol. Cell (2001) [Pubmed]
  34. Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Hayakawa, J., Mittal, S., Wang, Y., Korkmaz, K.S., Adamson, E., English, C., Ohmichi, M., Omichi, M., McClelland, M., Mercola, D. Mol. Cell (2004) [Pubmed]
  35. Tumors of unknown origin. Greco, F.A., Hainsworth, J.D. CA: a cancer journal for clinicians. (1992) [Pubmed]
  36. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. Keys, H.M., Bundy, B.N., Stehman, F.B., Muderspach, L.I., Chafe, W.E., Suggs, C.L., Walker, J.L., Gersell, D. N. Engl. J. Med. (1999) [Pubmed]
  37. Selective bladder preservation by combination treatment of invasive bladder cancer. Kaufman, D.S., Shipley, W.U., Griffin, P.P., Heney, N.M., Althausen, A.F., Efird, J.T. N. Engl. J. Med. (1993) [Pubmed]
  38. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. Williams, S.D., Stablein, D.M., Einhorn, L.H., Muggia, F.M., Weiss, R.B., Donohue, J.P., Paulson, D.F., Brunner, K.W., Jacobs, E.M., Spaulding, J.T. N. Engl. J. Med. (1987) [Pubmed]
WikiGenes - Universities